Product logins

Find logins to all Clarivate products below.


Stacey Chang-Douglass

Head of Health Economics and Director in Consulting

Stacey is Head of Health Economics and Director in Consulting at Clarivate.

Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.

Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.

Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.

Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.

Related resources

为何更方便的给药方式并未获得支付方青睐 为何更方便的给药方式并未获得支付方青睐
Blog February 26, 2026
为何更方便的给药方式并未获得支付方青睐
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规